HSF1 modulates lipid metabolism and ferroptosis in sarcopenia: a novel diagnostic biomarker and therapeutic target
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Methods and Results: RNA-seq GSE25941/GSE9103; WGCNA and LASSO/SVM/KNN/XGBoost/NNET shortlist six FRGs; HSF1 highest diagnostic AUC (0.9247); C2C12 silencing/overexpression assays measure lipid metabolism, ferroptosis and atrophy markers.
Technology: Methods and Results: RNA-seq GSE25941/GSE9103; WGCNA and LASSO/SVM/KNN/XGBoost/NNET shortlist six FRGs; HSF1 highest diagnostic AUC (0.9247); C2C12 silencing/overexpression assays measure lipid metabolism, ferroptosis and atrophy markers.
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- Methods and Results: RNA-seq GSE25941/GSE9103; WGCNA and LASSO/SVM/KNN/XGBoost/NNET shortlist six FRGs; HSF1 highest diagnostic AUC (0.9247); C2C12 silencing/overexpression assays measure lipid metabolism, ferroptosis and atrophy markers.
- Limitation / still unknown
- nockdown/overexpression assays measured associated lipid-metabolism, ferroptosis and atrophy effects.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2026.1727633/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.